Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab
Authors:
Open Access
- 11 July 2016
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 21 (6) , 1191-1195
Abstract
In order to help in selecting the optimum bone-modifying agent (BMA; zoledronic acid or denosumab), we investigated the impact of the BMA on the renal function of patients with bone metastases.Keywords
This publication has 16 references indexed in Scilit:
- Denosumab: a new option in the treatment of bone metastases from urological cancersOncoTargets and Therapy, 2012
- A single-dose study of denosumab in patients with various degrees of renal impairmentJournal of Bone and Mineral Research, 2012
- Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasisClinical & Experimental Metastasis, 2011
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind StudyJournal of Clinical Oncology, 2010
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working GroupJournal of Clinical Oncology, 2008
- Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled TrialJournal of Clinical Oncology, 2005
- Renal Failure with the Use of Zoledronic AcidNew England Journal of Medicine, 2003
- EpilepsyNew England Journal of Medicine, 2003
- Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study GroupJournal of Clinical Oncology, 2003